PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Inosine Pranobex→

Inosine Pranobex PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
36703-88-5
Molecular formula
C52H78N10O17
Molecular weight
1115.2 g/mol
Drug class
Immunomodulatory antiviral agentinosine pranobex complex
Mechanism of action
The exact mechanism is not fully established. It appears to modulate cell-mediated immune responses, including T-cell differentiation and lymphoproliferative responses, rather than acting directly on viral enzymes.
Indications / reported uses
  • Adjunctive treatment of selected viral infections in countries where inosine pranobex is authorised; exact indications vary by product and jurisdiction.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/inosine-pranobex · https://meshb.nlm.nih.gov/record/ui?ui=D007542 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Inosine Pranobex PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Inosine Pranobex Permitted Daily Exposure (PDE) report (the Inosine Pranobex PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Inosine Pranobex Occupational Exposure Limit (OEL) report (the Inosine Pranobex OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.